Regarding the CCL5-CCR5 axis blocking strategies, a CCR5 antagonist has been approved as a treatment for patients with liver metastases of advanced refractory colorectal cancers and preliminary results indicated that this approach can lead to clinical responses [125]. This evidence concerns the gene CCR5 and colorectal cancer.